MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.35
-0.21
-1.07%
After Hours: 19.35 0 0.00% 16:01 05/24 EDT
OPEN
19.26
PREV CLOSE
19.56
HIGH
19.59
LOW
18.69
VOLUME
306.55K
TURNOVER
0
52 WEEK HIGH
46.46
52 WEEK LOW
18.69
MARKET CAP
834.64M
P/E (TTM)
12.67
1D
5D
1M
3M
1Y
5Y
Regenxbio's Return On Capital Employed Overview
Regenxbio (NASDAQ:RGNX) brought in sales totaling $22.22 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 126.09%, resulting in a loss of $76.72 million.
Benzinga · 7h ago
Expert Ratings for Regenxbio
Over the past 3 months, 4 analysts have published their opinion on Regenxbio (NASDAQ:RGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the...
Benzinga · 8h ago
Morgan Stanley Adjusts REGENXBIO Price Target to $47 From $51, Maintains Overweight Rating
MT Newswires · 10h ago
5 Value Stocks In The Healthcare Sector
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be...
Benzinga · 05/16 14:43
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 05/16 13:39
Some REGENXBIO Inc. (NASDAQ:RGNX) Analysts Just Made A Major Cut To Next Year's Estimates
The analysts covering REGENXBIO Inc. ( NASDAQ:RGNX ) delivered a dose of negativity to shareholders today, by making a...
Simply Wall St. · 05/12 10:09
RGNX, FATE and ALVR are among after hours
Gainers: REGENXBIO  (RGNX) +8%. Passage Bio (PASG) +6%. Yellow Corporation (YELL) +6%. Fluence Energy (FLNC) +6%. Fate Therapeutics (FATE) +4%. Losers: Cytokinetics (CYTK) -5%. Golden Entertainment GDEN -5%. AlloVir (ALVR) -5%. Arcimoto (FUV) -4%.
Seekingalpha · 05/06 21:50
--Chardan Research Adjusts Price Target for REGENXBIO to $70 From $76, Maintains Buy Rating
MT Newswires · 05/05 14:17
More
No Data
Learn about the latest financial forecast of RGNX. Analyze the recent business situations of Regenxbio through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

22.22%Strong Buy
44.44%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RGNX stock price target is 51.33 with a high estimate of 70.00 and a low estimate of 25.00.
High70.00
Average51.33
Low25.00
Current 19.35
EPS
Actual
Estimate
0.242.264.296.31
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 259
Institutional Holdings: 37.57M
% Owned: 87.11%
Shares Outstanding: 43.13M
TypeInstitutionsShares
Increased
62
1.29M
New
31
1.11M
Decreased
57
2.16M
Sold Out
16
865.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.05%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Director
Allan Fox
President/Chief Executive Officer/Director
Kenneth Mills
Chief Financial Officer/Executive Vice President
Vittal Vasista
Chief Operating Officer/Executive Vice President
Curran Simpson
Executive Vice President/Chief Scientific Officer
Olivier Danos
Executive Vice President
Patrick Christmas
Executive Vice President
Steve Pakola
Lead Director/Independent Director
A. N. Karabelas
Independent Director
Daniel Abdun-Nabi
Independent Director
Jean Bennett
Independent Director
Alexandra Glucksmann
Independent Director
George Migausky
Independent Director
David Stump
Independent Director
Daniel Tasse
No Data
No Data
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates use adeno-associated virus (AAV) vectors from its gene delivery platform, called NAV Technology Platform. Its product candidate includes RGX-314, RGX-111, RGX-121, RGX-202, RGX 181 and RGX-381. RGX-314 is meant for the treatment of wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) and other anti-VEGF treated conditions. It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II). RGX-202 is its product candidate for the treatment of duchenne muscular dystrophy (DMD).

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.